Purpose: AZD2014 is a novel, oral, m-TORC 1/2 inhibitor that has shown in vitro and in vivo efficacy across a range of preclinical human cancer models.
Introduction
The PI3K pathway is deregulated in more than 50% of all cancers. Mechanisms of deregulation include activating mutations in PIK3CA and AKT and loss of function of tumor suppressor genes such as PTEN (1) . m-TOR consists of two essential complexes, TORC1 and TORC2 and is a crucial node in the PI3K signaling network (2) . Inhibition of TORC1 could lead to inhibition of cell growth and metabolism via inactivation of downstream targets such as p-S6, p-4EBP1, and p-GSK3B (3) . In addition, m-TORC2 is critical to AKT signaling (4) .
Drugs such as sirolimus, temsirolimus, and everolimus are allosteric inhibitors of m-TOR. Sirolimus is licensed for use in transplant medicine (5) and other allosteric m-TOR inhibitors such as temsirolimus and everolimus have been licensed for use in a variety of cancers (6) (7) (8) (9) (10) .
Preclinical studies have suggested that allosteric inhibition of m-TOR by a rapalog inhibits only m-TORC1 and leads to an increase in phosphorylation of AKT due to feedback loops (11) and continued activity of m-TORC2 (12) . This has been confirmed clinically in posttreatment biopsy samples in patients treated with rapalogs (13, 14) . The activation of AKT is hypothesized to be a mechanism of resistance to these agents.
AZD2014 is a rationally designed ATP competitive m-TORC1/2 inhibitor with an IC 50 of 2.81 nmol/L and has shown preclinical activity across a range of in vitro and in vivo preclinical models (15) . Preclinical experiments showed a 95% protein binding in human plasma and bioavailability of 29%. [ 14 C]-AZD2014 was extensively metabolized following a single dose in rats with N-hydroxymethyl and desmethyl components accounting for 25% and 10% of parent AUC in plasma, respectively. Urinary and faecal excretion in this model accounted for approximately 2% and 85% of dosed radioactivity, respectively. In human hepatocytes and heterologously expressed CYP isozymes, AZD2014 was primarily metabolized by CYP3A5 and CYP2C8 with some contribution from CYP3A4.
The primary aim of this first-in-human study was to investigate the safety and tolerability of AZD2014. The secondary aims included determining the pharmacokinetic (PK) profile, confirming target engagement by studying changes in pharmacodynamic (PD), proof-of-mechanism (POM), and proof-of-concept (POC) biomarkers in addition to documenting preliminary clinical activity.
The highest severely non-toxic dose in dogs was not established. The highest dose administered to dogs in a 1 month toxicology study was 5 mg/kg/d. The human equivalent dose of one sixth this dose level in a 60 kg human was 27 mg/d. However, the International Conference on Harmonization (ICH) S9 guideline recommended that the starting dose should be "a pharmacologically active dose that is reasonably safe to use." Using physiologically based pharmacokinetic modeling, the IC 50 value demonstrated in the U87-MG mouse xenograft model, and allowing for differences in plasma protein binding in man and mouse, suggests that a single dose of 50 mg would give plasma concentrations close to the IC 50 value at maximum concentration (C max ) in patients. Further exposures in patients following a 50 mg starting dose were expected to be consistent with the exposures that caused monitorable and reversible effects in the toxicology studies, with the exception of the testicular changes and partial recovery in bone marrow. Finally, AZD2014 was predicted to have a modest half-life of 4 hours, it was not anticipated that the subsequent repeat dosing phase at 50 mg twice daily (100-mg total-daily dose) would show significant accumulation. Thus, the proposed starting dose was 50 mg twice daily after the washout period.
TORC1/2 inhibitors that are currently under phase I evaluation or have completed phase I evaluation include AZD2014 (15), INK-128/MLN-128 (16, 17) , DS-3078a (18), OSI-027 (19, 20) , and AZD8055 (21, 22) .
Materials and Methods
This study used a rolling six dose-escalation design during the dose-escalation phase. At the recommended phase II dose, an expansion cohort to further characterize tolerability, PK and PD profiles, including pre-and posttreatment biopsies in a subset of patients, was instituted. Patients were recruited at the Royal Marsden and Christie Hospital NHS Foundation Trust in the UK following ethics committee approvals. Patients with advanced solid tumors who had already received standard-of-care treatment and had adequate organ function were eligible for the study. There was no difference between the eligibility criteria between doseescalation and -expansion cohorts of the study. Following informed, written consent, patients received a single run-in dose of AZD2014 in a liquid (solution) formulation. During the clinical trial, AZD2014 was administered orally, with patients fasting (except for water) for 2 hours before dosing and 1 hour after dosing. Dose-limiting toxicities (DLT) were evaluated during the run-in dose and the first 21 days of continuous dosing. Common toxicity criteria (CTC) grade 4 hematologic toxicity or any grade 3 or grade 4 non-hematologic toxicity was considered a DLT, with the exception of alopecia, inadequately treated grade 3 or 4 nausea and vomiting or isolated laboratory change without any clinical significance. Concomitant exposure to potent and moderate inhibitors and inducers of CYP3A4/5 and CYP2C8 were not permitted. Details of drugs and washout periods are mentioned in the Supplementary Data. Blood was drawn for PK and PD analysis over 24 hours. The PD samples for the run-in single dose were drawn at pre dose, 2 hours, 6 to 8 hours and 24 hours after dose. The patient then commenced continuous dosing of AZD2014 twice a day, 3 to 7 days later. The length of a cycle was 28 days. Adverse events were recorded using National Cancer Institute Common Toxicity Criteria 3.1. On days 15, 21, and 28, blood was collected over 12 hours to assess steady state PK profiles. Tumor biopsies were carried out between days 8 to 15. Patients were seen every week to assess safety. CT scans were carried out at baseline and every 8 weeks to assess disease response using RECIST 1.1. The drug concentrations in plasma were assessed using mass spectrometry (see Supplementary Data for details). PK analysis was carried out using Phoenix-WinNonLin v6 for NCA. The PD assays included p-4EBP1 in peripheral blood mononuclear cells (PBMC) using flow cytometry, p-AKT in platelet-rich plasma (PRP), which was performed using an immunoassay from Meso Scale Discovery. p-S6, p-AKT, p-4EBP1, and Ki67 in pre-and posttreatment biopsies were assessed using immunohistochemistry. A biopsy pair was considered evaluable for determination of inhibition of phosphorylation on therapy if two or more of the triplicate sections for each pretreatment sample had an H-score above 10 (see Supplementary Data for details of methods for PD analysis). Tumors of all patients entered into the study were not sequenced. The Drug Development Unit at The Institute of Cancer Research and The Royal Marsden runs a generic molecular characterization protocol (CCR 3171) that allows sequencing of patients' archival tumor blocks. Targeted exome sequencing of pretreatment tumor samples from 2 patients who had a partial response (PR) using the TruSeq panel on the MiSeq platform was carried out at The Institute of Cancer Research. FDG PET scans were done at baseline and on day 8 AE 2 days of continuous dosing. The interval between the administration of PET tracer and scan was standardized to 1 hour.
Results
A total of 56 patients across a dose range of 25 to 100 mg twice daily were treated on this phase I study (n ¼ 23 in part A and n ¼ 33 in part B). Nineteen male and 37 female patients
Translational Relevance
The m-TOR consists of two essential complexes, m-TORC1 and m-TORC2. Conventional, allosteric m-TOR inhibitors inhibit m-TORC1 but not m-TORC2 function. This may lead to feedback loops activating PI3K via IRS1 and continued phosphorylation of AKT at Ser473 by uninhibited m-TORC2. AZD2014 is a dual m-TORC1 and m-TORC2 kinase inhibitor. This study identified the maximally tolerated dose and schedule for AZD2014 as 50 mg twice daily. It was possible to demonstrate m-TORC1 inhibition in normal tissue and tumor as evidenced by reduction in the phosphorylation of 4EBP1 and S6, respectively, and importantly, m-TORC2 inhibition (reduction in p-AKT) in normal tissue and tumor. Furthermore, there was evidence of reduced metabolism (reduction in SUV max in FDG PET scans). Other key findings included reduction in proliferation (Ki67 reduction in posttreatment biopsies and two partial responses). The dual m-TORC1/2 inhibitor AZD2014 should be investigated further.
were treated, and the median age was 59 (range, 33-76). The most common tumor type recruited to the study was breast cancer (15/56). Details of the demographic profile, ECOG performance status, and tumor types treated are listed in Supplementary Table S1 .
Dose escalation
The starting dose was 50 mg twice daily and, as no DLTs were seen in 6 patients, the dose was doubled to 100 mg twice daily. As there were four of four DLTs, an intermediate dose of 70 mg twice daily was explored. A total of 5 patients were dosed in this cohort, but one patient withdrew consent before becoming evaluable for the dose decision. A further two of four evaluable patients had a DLT at 70 mg twice daily, and thus the remaining two patients who had consented to this cohort received 50 mg twice daily. Thus, 50 mg twice daily was considered the maximally tolerated dose. Fifty mg twice daily was both the starting dose and the MTD and this dose showed PD activity in normal tissue. It is possible that future combination studies would use lower doses of AZD2014, and thus a further cohort of 6 patients were treated at 25 mg twice daily to further characterize PK and PD profiles over a range of doses of AZD2014 that could be used in the future. Subsequently, 50 mg twice daily was declared the recommended phase II dose (RP2D) and a further 33 patients were treated to further evaluate toxicity, PK and PD.
Dose-limiting toxicities
At the dose of 100 mg twice daily, DLTs were seen in four of four patients. In all instances these were CTC grade 2 or 3 fatigue, occurring within the first week of treatment. The fatigue was reversible on discontinuation of the drug. At a dose of 70 mg twice daily, DLTs were seen in two of four evaluable patients treated, with grade 3 fatigue and grade 3 mucositis in one patient and grade 3 fatigue in another. All events were reversible on cessation of AZD2014.
Adverse events
The adverse events (AE) that occurred in >15% of patients at the RP2D of 50 mg twice daily are listed in Table 1 . All AEs reported in this paragraph pertain to patients treated at 50 mg twice daily on parts A and B (Table 1) . Fatigue was the most commonly seen AE in 32 of 41 (78%) patients; however, only 2 of 41 (5%) were grade 3 or higher and this was reversible on interruption of dosing. Gastrointestinal symptoms such as nausea, mucositis, diarrhea, and vomiting were seen in 21 of 41 (51%), 20 of 41 (49%), 17 of 41 (42%), and 12 of 41 (29%), respectively; however, less than 5% of these AEs were grade 3 or 4. Nausea and vomiting were well controlled by antiemetics, such as domperidone, if necessary, and the grade 1 and 2 diarrhea did not consistently require treatment. Mucositis was grade 1 and 2 in most instances and patients responded to mouth-washes and did not require dose interruptions due to it. A predominantly maculopapular rash was observed in 17 of 41 (42%) of patients and less than 5% of these were grade 3 or higher. Lower respiratory tract infections were seen in 7 of 41 (17%), and it was grade 3 in only 1 of 41 (2%). Interestingly, no patients were diagnosed with pneumonitis. The most common laboratory abnormality was anemia, with 7 of 41 (17%) having recorded grade 1 and 2 anemia; given the advanced cancer and degrees of comorbidities in these patients, it was difficult to attribute this specifically to AZD2014. Hyperglycemia was seen in 5 of 41 (12%), 0 of 5 (0%), and 2 of 4 (50%) of patients treated at 50, 70, and 100 mg twice daily, respectively. At the RP2D of 50 mg twice daily, no grade 3 or 4 hyperglycemia was seen. Furthermore, no grade 3 or above hypercholesterolemia or triglyceridemia was seen in this cohort. ECG monitoring revealed an increase in QT corrected Bazett's formula (QTCB) and a reduction in QTCB by 30 to 60 msec in 3 of 41 (7%) and 5 of 41 (12%), respectively, thus showing no defined trend for increase or decrease in QTCB. Because of the modest number of patients treated across different dose levels and the standard timing of ECG done, a formally powered testing of the relationship of plasma concentrations to QTCB has not been done. At the RP2D of 50 mg twice daily, 10 of 41 (24.4%) had an interruption and 1 of 41 (2.4%) had a dose reduction due to an AE.
Pharmacokinetics
Following oral administration, AZD2014 was rapidly absorbed, with median time to peak following a single dose between 0.5 and 1 hour across the 25 to 100 mg dose range. Terminal elimination half-life was approximately 3 hours. Geomean exposure (AUC and C max ) increased greater than proportionally with increasing dose and interpatient variability was seen with exposures overlapping across the dose range (Fig. 1A and B and Table 2 ). At dose of 50 mg twice daily (n ¼ 27), the G mean Figure 1 . Pharmacokinetic profile of AZD2014. A, concentration of drug over time across a dose range of 25 to 100 mg following a single dose. In the range of doses studied, there was considerable overlap of plasma concentrations across different cohorts. B, the relationship of AUC to the dose across the dose range studied. C min SS was 169.5 ng/mL, with a coefficient of variation (CV) of 163.6% and a range of 0 to 2,120 ng/mL.
Pharmacodynamics
In samples of patients treated at 50 mg, phosphorylation of 4E-BP1 was reduced in PBMCs to approximately À45% and À41% of baseline at 2 and 6 to 8 hours following a single dose of AZD2014, respectively. Phosphorylation of AKT (S473) in PRP was reduced to À62% and À37% of baseline at 2 and 6 to 8 hrs, respectively. These data indicate inhibition of m-TORC1 and m-TORC2 ( Fig. 2A and B) . Changes in phosphorylation of 4EBP-1 and AKT were seen at dose levels of 50 to 70 mg and, importantly, changes in phosphorylation of AKT were seen at doses below the MTD (25 mg cohort; Fig. 2C and D) . POM PD biomarkers such as p-S6, p-4EBP1 (m-TORC1), and p-AKT (m-TORC2), and POC biomarkers (Ki67) were assessed in pre-and posttreatment biopsies and showed evidence of target inhibition ( Fig. 3A-E ). Of note, 11 patients in part B (50 mg twice daily) had paired FDG PET scans, 8 of 11 patients showed a reduction of SUV max , with 3 of 11 attaining a PR (30% reduction in SUV max ; Fig. 3F ).
Efficacy
There were two PRs in the study. The first was a patient with acinar pancreatic cancer who had previously responded to two lines of gemcitabine-based treatment. The patient had a maintained PR and was on treatment for six cycles. The patient was found to have KRAS, PDGFRA, APC, ERB4, KIT, and FBXW7 mutation. The second patient to respond was a patient with estrogen receptor (ER)-positive breast cancer who had six prior lines of chemotherapy and one line of hormonal treatment for her metastatic breast cancer. She received AZD2014 treatment for four cycles. Her tumor had a mutation in HRAS, NRAS, TP53, and ERBB2 (Fig. 4) . In addition, 2 patients, one each with ovarian and Figure 2 . PD profile of AZD2014 in normal tissue. A, the reduction of p-4EBP1 levels in monocytes after a single dose of AZD2014 at the RP2D of 50 mg twice daily. The mean percentage of change in p-4EBP1 after a single 50-mg twice-daily (BD) dose of AZD2014 in part B was À45% (n ¼ 14; CI, À60% to À30%) at 2 hours and À41% (n ¼ 14; CI, À52% to À29%) at 6 to 8 hours. At 24 hours (12 hours after the second twice-daily dose), the mean change from baseline was À21% (n ¼ 13; CI, À39% to À3%). B, the reduction of p-AKT levels in PRP after a single dose of AZD2014 at the RP2D of 50 mg twice daily. The mean percentage of change was À62% (n ¼ 32; CI, À70% to À54%) at 2 hours and À37% (n ¼ 32; CI, À47% to À27%) at 6 to 8 hours. At 24 hours (12 hours after the second twice-daily dose), the mean change from baseline was À2% (n ¼ 32; CI, À26% to þ22%). C, the percentage of change from baseline in p-4EBP1 in PBMCs across dose levels 50 to 100 mg twice daily at 2 hours after dose. The columns on the waterfall plot represent individual patients. D, the percentage of change from baseline in the reduction of p-AKT across dose levels 25 to 100 mg twice daily in PRP at 2 hours after dose.
endometrial cancer, had prolonged stable disease and remained on treatment for more than 1 year.
Discussion
The toxicity profile of AZD2014 had similarities with other TORC 1/2 inhibitors and more generally with allosteric m-TOR inhibitors and these were rash, mucositis, and fatigue (17, 18, 20, (22) (23) (24) (25) . At 50-mg twice-daily continuous dosing AZD2014 was well tolerated. Interestingly, in this present study there were no instances of grade 3 and 4 hyperglycemia that had been seen in clinical trials of m-TOR inhibitors (23) (24) (25) . Patients with diabetes were excluded and all patients had to have a fasting glucose of less than 126 mg/dL (7 mmol/L). Given previous experience of hyperglycemia seen with m-TOR inhibitors, it is not known how AZD2014 would affect glycemic control of patients with type I or type II diabetes. Renal (20) , hepatic (22) , and left ventricular dysfunction (20) seen with other m-TORC 1/2 inhibitors were not seen in patients treated with AZD2014. Of note, there were no instances of pneumonitis, seen more generally across m-TOR inhibitors (7, 9, 26) in this study. The tolerability of once a day AZD2014 given continuously and twice a day dosing given intermittently (2 days every week) has been subsequently studied and the results will be presented separately when the studies are complete.
The pharmacokinetic profile of AZD2014 showed rapid absorption. Although the elimination half-life of AZD2014 was approximately 3 hours and is shorter than allosteric m-TOR inhibitors such as everolimus, temsirolimus, or ridaforolimus, which have half-lives of approximately 24 hours or longer (23) (24) (25) , it allows twice-daily dosing and the possibility of more flexible intermittent dosing when used in combination with other anticancer drugs such as cytotoxic chemotherapy or other targeted agents. There are multiple reasons that could give rise to the interindividual pharmacokinetic variability. Preliminary analysis of some of the potential reasons have been investigated and include differences in the percentage of drug bound to protein between patients, but a preliminary investigation using measured AZD2014-free plasma concentrations instead of the usual way of using total plasma concentrations to determine PK parameters found that they were equally variable and the relationships with PD no better. It is also not likely to be formulation performance because the drug is a solution, and therefore does not require a dissolution step before being absorbed. It could be hypothesized that differences in CYP metabolizing enzymes and/or transporter enzymes may affect ability to clear and/or distribute the drug in and out of tissue and affect PK variability. The data in this publication relate to the liquid formulation of AZD2014. Further studies have been conducted to evaluate the PK of the tablet formulation and the effect of food on exposure to AZD2014 and will be submitted for publication once complete. AZD2014 produces >70% total growth inhibition (TGI) at 4,500 nmol/LÁh free weekly AUC, and !100% TGI at 17,000 nmol/LÁh in MCF7 xenograft models and human PK achieved in this trial was in the range that would be efficacious in this model (on average the 50-mg twice-daily solution dose achieved a free weekly AUC of 11,050 nmol/LÁh, with the vast majority of patients achieving more than 4,500 nmol/LÁh). To provide the comparison of the clinical exposure with the preclinical data, the measured clinical exposure of AZD2014 reported in ngÁh/mL of total (bound and unbound) drug was converted to nmol/LÁh of free (unbound) drug using the molecular weight of AZD2014 (462.56 g/mol) and the measured human plasma protein binding of 5.47% free (unbound) drug.
The PD profile of AZD2014 showed target engagement in normal tissue. POM biomarkers of m-TORC1 and m-TORC2 inhibition, that is, reduction in levels of p-4EBP1 in PBMCs and p-AKT in PRP, respectively, were seen at 2 to 8 hours but recovered at 24 hours following a single dose of AZD2014, supporting a twice a day schedule. Importantly, reduction in p-AKT was seen at the 25 mg cohort, suggesting PD activity at this dose if dose reductions are necessary in future trials. Substantial interindividual variability was seen in the PK profile and this is likely to influence the PD profile seen in this study. Further studies evaluating PK, PD, and PK-PD profiles of the tablet formulation that will be taken forward into later phase clinical trials are warranted. Crucially, it was possible to demonstrate reduction of p-S6 (m-TORC1 inhibition) in all evaluable posttreatment biopsies. Reduction in p-AKT levels was seen in three of four assessable posttreatment biopsies, and no instances of induction of phosphorylation of AKT were seen in these samples. This is in contrast with increase in phosphorylation of AKT due to a feedback loop via IRS1, which is a possible mechanism of resistance seen when tumor tissue is exposed to allosteric m-TOR inhibitors (13, 14) . In addition to the POM PD biomarkers discussed above, more distal, POC biomarkers such as reduction of proliferation (Ki67) and reduction in metabolism (FDG-PET scans) also support evidence of target inhibition in tumor. Overall PD biomarkers have been informative to the trial; normal tissue has shown a PD engagement at 25 to 100 mg twice daily, which will be taken into consideration while designing intermittent schedules and combination studies with dosing a higher or lower doses of AZD2014. At the MTD of 50 mg twice daily pre-and postbiopsies and FDG PET scans have confirmed target engagement in tumor tissue.
Single-agent efficacy was seen in a population of heavily pretreated solid tumors. Interestingly, both patients who responded did not have a PIK3CA or AKT mutation; however, the tumors did have activating mutations upstream of m-TORC1/2.
The recommended phase II dose of AZD2014 took into consideration toxicity, PK and PD findings. At this dose, the drug was well tolerated, exhibited a favorable PK profile, showed robust evidence of target engagement and showed evidence of clinical efficacy as a single agent. PD studies indicated target engagement in normal tissue in the range 25 to 100 mg; thus, these doses could be explored in future intermittent schedules or taken into con- 
